Saatja: Ingus Kaufmanis <
[email protected]>
Saadetud: 26.04.2021 12:14
Teema: Fwd: Proposal to implement a proven innovative diagnostic
technology that would decrease patient Length of Stay (LOS) in Intensive
care Units (ICU) and support the increase bed turnover during COVID-19
pandemic.
Dear,
SIA HYDROX in cooperation with our represented manufacturer Accelerate
Diagnostics has prepared a proposal for the Estonian healthcare system to
introduce proven diagnostic technology that would reduce the length of
stay (LOS) in intensive care units (ICU) and support the increase of bed
turnover during the COVID-19 pandemic.Please see the attached Accelerate
Diagnostics letter. All related documents and publications are also
attached.This is an essential technology:- it helps to identify earlier
secondary infections and their susceptibility to antibiotics,- it will
help to free up beds more quickly and improve bed turnover, which could
to some extent help to address the growing problem of insufficient beds
in the current situation.We currently have 2 Accelerate Pheno systems
available on site, each with 2 work modules, which we can immediately
deliver to Estonian hospitals and implement in routine testing.Reagents
and natural accessories for the systems are freely available and without
restriction quotas.We will be happy for your positive response and the
opportunity to meet in person / online platforms to discuss this offer /
solution.
With my best regards,
--
With best regards,
Ingus Kaufmanis
Sales director
Hydrox SIA | Lizuma street 1, Riga, LV-1006, Latvia
M: +371 22087790 | W: +371 67551517 | F: +371 67551599
E: ingus|